Eli Lilly & Co. and Novo Nordisk A/S plan to start selling their popular obesity shots to employers through a new approach ...

Four patients in Denmark, who experienced vision loss after using Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic, have been granted compensation, the Danish Patient ...

Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...

Apple became the first $1 trillion company on U.S. public markets in 2018. Six of the eight companies to follow in Apple’s ...

Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the market as Mounjaro for Type 2 diabetes and as Zepbound for weight management ...

People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for ...

In today’s Pharma Pulse, learn how digital pharmacy safety gaps, Novo Nordisk’s introductory programs for Wegovy and Ozempic, and Scott Gottlieb’s new role at UnitedHealth are shaping patient access ...

​Novo Nordisk A/S (NYSE: NVO) is one of the Most Profitable Stocks to Buy Now. On November 17, Reuters reported that Novo ...

Novo Nordisk goes "on the offensive" following Trump deal that also included rival Eli Lilly, putting an exclamation point on ...

Novo Nordisk announced on Monday that it is lowering costs for weight loss and diabetes drugs, weeks after it struck a deal ...

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...

On Monday, Novo Nordisk announced a discount on its popular drugs for diabetes and obesity, Ozempic and Wegovy, cutting ...